Buruli ulcer appears to be a largely toxin-mediated disease, the development of an anti-toxin may be one of the approaches towards vaccine development and could also be therapeutically useful. Another factor which supports the feasibility of developing a subunit vaccine against M. ulcerans is that infection is largely extracellular. Therefore antibodies against mycobacterial cell surface structures may have protective activity.
- To develop an anti-toxin for use as a vaccine.
- To search and evaluate protein-based vaccine candidates.